当前位置： SCI文献检索 > Diabetes Technology & Therapeutics期刊下所有文献 > Waist circumference identifies primary school children with metabolic syndrome abnormalities.

Waist circumference identifies primary school children with metabolic syndrome abnormalities.

Abstract：

OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), waist circumference, and blood pressure were determined in all subjects. The subgroup had Tanner stage, glucose, lipid profile, and insulin assays. The BMI of the 5,103 children was used to calculate our z scores. To determine which marker was a better predictor for metabolic syndrome, a receiver operating characteristic (ROC) curve was generated for BMI and waist circumference, with metabolic syndrome as the dichotomous variable. RESULTS:Over 530 children (8.7 +/- 2.4 years) 6% (n = 32) were obese (BMI >95(th) percentile; z BMI = 2.55), 13.6% (n = 72) were overweight (OW) (85(th) < BMI < 95(th) percentile; z BMI = 1.45), and 80.4% (n = 426) were non-OW (BMI <85(th) percentile; z BMI = - 0.14). Fifty-eight percent [95% confidence interval (CI) 53, 6], 22.8% (95% CI 19, 27), 15.5% (95% CI 12, 19), and 4.1% (95% CI 2, 6) were Tanner stage I, II, III, and IV, respectively. Metabolic syndrome was present in 9.4% overall, 6% of the non-OW, 22.2% of the OW, and 31% in the obese group (P < 0.01). The differences between ROC areas were not significant (0.009) (95% CI -0.035 to 0.053; P = 0.679) for BMI and waist circumference. The optimal threshold for waist circumference percentile was 71.3 with a sensitivity and specificity of 58.9 (95% CI 48.4, 68.9) and 63.1 (95% CI 58.4, 67.7), respectively. CONCLUSIONS:Waist circumference and BMI predict metabolic syndrome abnormalities in children. Waist circumference > or =75(th) percentile could be the optimal threshold to predict metabolic syndrome in children.

journal_name

Diabetes Technol Ther

journal_title

Diabetes technology & therapeutics

authors

Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

doi

10.1089/dia.2006.0017

subject

Has Abstract

pub_date

2007-04-01 00:00:00

pages

149-57

issue

2

eissn

1520-9156

issn

1557-8593

journal_volume

9

pub_type

杂志文章,多中心研究

相关文献

Diabetes Technology & Therapeutics文献大全
  • Enzymatic fluorescent microsphere glucose sensors:evaluation of response under dynamic conditions.

    abstract：:Most previous attempts at the development of a "smart tattoo" for glucose monitoring in diabetes--implantable fluorescent microspheres that can be implanted intradermally and interrogated transdermally using light--have focused on the encapsulation of a competitive binding assay for glucose within hydrogel microsphere...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2006.8.288

    authors： Brown JQ,Srivastava R,Zhu H,McShane MJ

    更新日期：2006-06-01 00:00:00

  • The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population.

    abstract：BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2013.0288

    authors： Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

    更新日期：2014-05-01 00:00:00

  • Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects.

    abstract：BACKGROUND:Continuous glucose monitoring is a useful tool for the achievement of improved glucose control in patients with diabetes. We tested the ability of a novel noninvasive continuous glucose monitor to track glucose excursions. METHODS:The novel noninvasive Aprise sensor (Glucon Inc., Boulder, CO) utilizes the p...

    journal_title：Diabetes technology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1089/dia.2006.0059

    authors： Weiss R,Yegorchikov Y,Shusterman A,Raz I

    更新日期：2007-02-01 00:00:00

  • Virtual Coaching to Enhance Diabetes Care.

    abstract：:Rates of diabetes are increasing worldwide and there is not a sufficient clinical workforce to care for these patients. Diabetes-related apps are a feasible way to provide diabetes education to large numbers of people with diabetes but attrition rates are high. Apps enhanced by virtual coaching may be a way to circumn...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1089/dia.2019.0016

    authors： Ramchandani N

    更新日期：2019-06-01 00:00:00

  • Area of the diabetic ulcers estimated applying a foot scanner-based home telecare system and three reference methods.

    abstract：BACKGROUND:Diabetic foot ulcer area is a basic parameter used for monitoring the wound healing and effectiveness of the treatment applied. TeleDiaFoS (developed earlier in collaboration with the Department and Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland) is one of jus...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2011.0082

    authors： Ladyzynski P,Foltynski P,Molik M,Tarwacka J,Migalska-Musial K,Mlynarczuk M,Wojcicki JM,Krzymien J,Karnafel W

    更新日期：2011-11-01 00:00:00

  • Diabetes registries: where we are and where are we headed?

    abstract：:Disease registries are a searchable list of all patients with a particular chronic condition that often interface with an electronic medical record. The well-designed registry links all members of the patient's health team and provides key information for patients and physicians. The critical impact of a registry is t...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2008.0057

    authors： Khan L,Mincemoyer S,Gabbay RA

    更新日期：2009-04-01 00:00:00

  • Point accuracy of interstitial continuous glucose monitoring during exercise in type 1 diabetes.

    abstract：BACKGROUND:Previous studies of aerobic exercise have found lower sensor accuracy during exercise. Whether or not resistance exercise would also be associated with lower sensor accuracy has not yet been examined. This study sought to investigate the accuracy of continuous glucose monitoring sensor values at rest, during...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2012.0182

    authors： Yardley JE,Sigal RJ,Kenny GP,Riddell MC,Lovblom LE,Perkins BA

    更新日期：2013-01-01 00:00:00

  • Characterization of Daily Glycemic Variability in Subjects with Type 1 Diabetes Using a Mixture of Metrics.

    abstract：: Background: Glycemic variability (GV) is an important component of glycemic control for patients with type 1 diabetes (T1D). The inadequacy of existing measurements lies in the fact that they view the variability from different aspects, so that no consensus has been reache...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2019.0250

    authors： Zheng F,Jalbert M,Forbes F,Bonnet S,Wojtusciszyn A,Lablanche S,Benhamou PY

    更新日期：2020-04-01 00:00:00

  • Insulin Pump Settings During Breastfeeding in Women with Type 1 Diabetes.

    abstract：: Background: We aimed to explore insulin pump settings in breastfeeding women with type 1 diabetes. Methods: Thirteen unselected breastfeeding women with type 1 diabetes on insulin pump therapy were included consecutively from A...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2019.0280

    authors： Nørgaard SK,Nørgaard K,Roskjær AB,Mathiesen ER,Ringholm L

    更新日期：2020-04-01 00:00:00

  • Administration of Biosimilar Insulin Analogs: Role of Devices.

    abstract：:With the expiration of patent protection for several originator insulin analog molecules, the availability of insulin analog copies is set to increase. Many regulatory authorities have developed, and continue to refine, guidelines for the approval of biosimilar insulin analogs. Aspects such as the structure, pharmacok...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1089/dia.2016.0263

    authors： Heinemann L,Fritz I,Khatami H,Edelman SV

    更新日期：2017-02-01 00:00:00

  • Non-invasive glucose measurement technologies: an update from 1999 to the dawn of the new millennium.

    abstract：:There are three main issues in non-invasive (NI) glucose measurements: namely, specificity, compartmentalization of glucose values, and calibration. There has been progress in the use of near-infrared and mid-infrared spectroscopy. Recently new glucose measurement methods have been developed, exploiting the effect of ...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1089/dia.2004.6.660

    authors： Khalil OS

    更新日期：2004-10-01 00:00:00

  • A tale of two compartments: interstitial versus blood glucose monitoring.

    abstract：:Self-monitoring of blood glucose was described as one of the most important advancements in diabetes management since the invention of insulin in 1920. Recent advances in glucose sensor technology for measuring interstitial glucose concentrations have challenged the dominance of glucose meters in diabetes management, ...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1089/dia.2009.0002

    authors： Cengiz E,Tamborlane WV

    更新日期：2009-06-01 00:00:00

  • Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes.

    abstract：BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1089/dia.2013.0369

    authors： Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

    更新日期：2014-09-01 00:00:00

  • Time is glucose, can't miss gestational diabetes.

    abstract：BACKGROUND:Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes, if not treated. International guidelines recommend screening "all or high-risk women" at the initial prenatal visit, when a fasting plasma glucose (FPG) between 92 and 126 mg/dL is diagnostic for GDM. However, glucose testing ...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2011.0225

    authors： Festa R,Carta M,Ceriello A,Testa R

    更新日期：2012-05-01 00:00:00

  • A pilot study of the SPRINT protocol for tight glycemic control in critically Ill patients.

    abstract：BACKGROUND:Stress-induced hyperglycemia is prevalent in critical care, even in patients with no history of diabetes. Increased counter-regulatory hormone response increases gluconeogenesis and effective insulin resistance, which can be exacerbated by drug therapy. Control of blood glucose levels to the 4.0-6.1 mmol/L r...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2006.8.449

    authors： Lonergan T,Compte AL,Willacy M,Chase JG,Shaw GM,Hann CE,Lotz T,Lin J,Wong XW

    更新日期：2006-08-01 00:00:00

  • Nocturnal continuous glucose monitoring: accuracy and reliability of hypoglycemia detection in patients with type 1 diabetes at high risk of severe hypoglycemia.

    abstract：BACKGROUND:A reliable method to detect biochemical nocturnal hypoglycemia is highly needed, especially in patients with recurrent severe hypoglycemia. We evaluated reliability of nocturnal continuous glucose monitoring (CGM) in patients with type 1 diabetes at high risk of severe hypoglycemia. PATIENTS AND METHODS:Sev...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1089/dia.2013.0004

    authors： Bay C,Kristensen PL,Pedersen-Bjergaard U,Tarnow L,Thorsteinsson B

    更新日期：2013-05-01 00:00:00

  • Alternative delivery of insulin via eye drops.

    abstract：BACKGROUND:Various insulin delivery systems have been considered for systemic absorption other than injections. Although the ocular route has been suggested, its use is limited by the amount of insulin absorbed systemically via eyes. In order to improve the absorption rate of insulin into systemic circulations, the eff...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2005.7.695

    authors： Xuan B,McClellan DA,Moore R,Chiou GC

    更新日期：2005-10-01 00:00:00

  • A highly sensitive immunoassay resistant to autoantibody interference for detection of the diabetes-associated autoantigen glutamic acid decarboxylase 65 in blood and other biological samples.

    abstract：BACKGROUND:Glutamic acid decarboxylase-65 (GAD65) is a major autoantigen in autoimmune diabetes and is discharged from injured islet beta cells. GAD65 may also be released by transplanted islets undergoing immunological rejection. To test hypotheses regarding the utility of GAD65 as a biomarker for transplant rejection...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2006.8.207

    authors： Waldrop MA,Suckow AT,Hall TR,Hampe CS,Marcovina SM,Chessler SD

    更新日期：2006-04-01 00:00:00

  • The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease.

    abstract：BACKGROUND:Vascular endothelial growth factor (VEGF) is involved in the pathogenesis of diabetic microvascular disease. Most diabetes patients have higher serum levels of ferritin that may participate in diabetic vascular complications through high oxidative stress induced by iron. However, the mechanistic link between...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2013.0181

    authors： Guo L,Jiang F,Tang YT,Si MY,Jiao XY

    更新日期：2014-04-01 00:00:00

  • Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.

    abstract：: Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an invest...

    journal_title：Diabetes technology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1089/dia.2019.0286

    authors： Sherr JL,Buckingham BA,Forlenza GP,Galderisi A,Ekhlaspour L,Wadwa RP,Carria L,Hsu L,Berget C,Peyser TA,Lee JB,O'Connor J,Dumais B,Huyett LM,Layne JE,Ly TT

    更新日期：2020-03-01 00:00:00

  • Determining clinical and psychological benefits and barriers with continuous glucose monitoring therapy.

    abstract：BACKGROUND:Preventing the complications of diabetes requires tight control and minimizing blood glucose fluctuation. Pursuing these goals increases the risk of severe hypoglycemia. The authors hoped to identify if using continuous glucose monitoring (CGM) decreased the incidence of severe hypoglycemia, resulted in less...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2009.0121

    authors： Halford J,Harris C

    更新日期：2010-03-01 00:00:00

  • Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).

    abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1089/dia.2013.0074

    authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

    更新日期：2013-11-01 00:00:00

  • Validation of the SoloSTAR insulin pen.

    abstract：BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

    journal_title：Diabetes technology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1089/dia.2008.0079

    authors： Schwartz S,Vlajnic A

    更新日期：2008-10-01 00:00:00

  • The design and performance of the exubera pulmonary insulin delivery system.

    abstract：:The Exubera system (Pfizer, New York, NY/Nektar Therapeutics, San Carlos, CA) is an integration of five major new technologies: protein formulation, powder processing, powder filling, drug packaging, and delivery device. The product provides a simple interface, where the patient interacts only with the delivery device...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2007.0222

    authors： Harper NJ,Gray S,De Groot J,Parker JM,Sadrzadeh N,Schuler C,Schumacher JD,Seshadri S,Smith AE,Steeno GS,Stevenson CL,Taniere R,Wang M,Bennett DB

    更新日期：2007-06-01 00:00:00

  • In vivo glucose monitoring using dual-wavelength polarimetry to overcome corneal birefringence in the presence of motion.

    abstract：OBJECTIVE:Over the past 35 years considerable research has been performed toward the investigation of noninvasive and minimally invasive glucose monitoring techniques. Optical polarimetry is one noninvasive technique that has shown promise as a means to ascertain blood glucose levels through measuring the glucose conce...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2012.0070

    authors： Pirnstill CW,Malik BH,Gresham VC,Coté GL

    更新日期：2012-09-01 00:00:00

  • Impact of glycemic control on heart rate variability in youth with type 1 diabetes: the SEARCH CVD study.

    abstract：AIM:This study explored the role of glycemic control on cardiac autonomic function, measured by heart rate variability (HRV), in youth with type 1 diabetes. PATIENTS AND METHODS:A retrospective cohort of 345 youth with type 1 diabetes (mean age, 18.5 years; duration, 10 years) participating in the SEARCH for Diabetes ...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1089/dia.2013.0147

    authors： Jaiswal M,Fingerlin TE,Urbina EM,Wadwa RP,Talton JW,D'Agostino RB Jr,Hamman RF,Daniels SR,Marcovina SM,Dolan LM,Dabelea D

    更新日期：2013-12-01 00:00:00

  • Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.

    abstract：BACKGROUND:Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS:This double-blind, randomized, crossover active-controlled trial compared 2...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1089/dia.2016.0350

    authors： Bode BW,Johnson JA,Hyveled L,Tamer SC,Demissie M

    更新日期：2017-01-01 00:00:00

  • Continuous Glucose Monitoring, Glycemic Variability, and Excessive Fetal Growth in Pregnancies Complicated by Type 1 Diabetes.

    abstract：BACKGROUND:To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM). METHODS:In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemi...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2017.0443

    authors： Mulla BM,Noor N,James-Todd T,Isganaitis E,Takoudes TC,Curran A,Warren CE,O'Brien KE,Brown FM

    更新日期：2018-06-01 00:00:00

  • Evaluation of Blood Glucose Meter Efficacy in an Antenatal Diabetes Clinic.

    abstract：BACKGROUND:The optimal treatment of diabetes in pregnancy requires accurate measurement of blood glucose levels, in order to minimize adverse outcomes for both mother and neonate. Self-monitoring of blood glucose is routinely used to measure glycemic control and to assess whether treatment targets are being met; howeve...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章,收录出版

    doi：10.1089/dia.2015.0104

    authors： McGrath RT,Donnelly VC,Glastras SJ,Preda VA,Sheriff N,Ward P,Hocking SL,Fulcher GR

    更新日期：2016-02-01 00:00:00

  • Effects of sleep apnea severity on glycemic control in patients with type 2 diabetes prior to continuous positive airway pressure treatment.

    abstract：BACKGROUND:Obstructive sleep apnea (OSA), a highly prevalent condition, is independently associated with increased risks of developing type 2 diabetes mellitus (T2D) and metabolic syndrome. It is unclear, however, if the severity of OSA has any impact on glycemic control among patients with T2D. We therefore aimed to d...

    journal_title：Diabetes technology & therapeutics

    pub_type： 杂志文章

    doi：10.1089/dia.2011.0005

    authors： Pillai A,Warren G,Gunathilake W,Idris I

    更新日期：2011-09-01 00:00:00